SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers

Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy

(2021) Claudia Alteri et al.   Nature Communications

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

(2021) Charlotte Manisty et al.   LANCET

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

(2021) Maria Prendecki et al.   LANCET

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

(2021) Sharon Amit et al.   LANCET

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

No evidence of SARS-CoV-2 circulation in the framework of influenza surveillance between October 2019 and February 2020 in Lombardy, Italy

(2021) Federica Giardina et al.   Travel Medicine and Infectious Disease

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay

(2021) Irene Cassaniti et al.   CLINICAL MICROBIOLOGY AND INFECTION

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

(2021) Yoel Angel et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

(2021) Eleftheria Vasileiou et al.   LANCET

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

(2021) Eric J Haas et al.   LANCET

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

(2021) Matan Levine-Tiefenbrun et al.   NATURE MEDICINE

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

(2021) Jamie Lopez Bernal et al.   BMJ-British Medical Journal

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

(2021) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study

(2021) Francesca Rovida et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

(2021) Emma Pritchard et al.   NATURE MEDICINE

Quantifying the risk of SARS‐CoV‐2 reinfection over time

(2021) Eamon O Murchu et al.   REVIEWS IN MEDICAL VIROLOGY

Covid-19 — The Search for Effective Therapy

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

(2020) Elena Percivalle et al.   Eurosurveillance

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE